What brokers need to clarify about employer pharmacy benefit and PBM strategy before Q2
The conversation brokers should be having right now
If you are a broker, this is the time of year when your mind starts shifting into strategy mode. Renewal feels far away, but Q2 conversations are right around the corner. Employers are asking questions. Budgets are tightening. And pharmacy spend keeps creeping up whether anyone is paying attention to it or not.
Here is the challenge. Most employers believe they understand their prescription costs. They see a renewal number. They review a summary report. They compare this year to last year. On the surface, it feels manageable.
But pharmacy is rarely simple.
Prescription drug spending now represents nearly 20% of total healthcare spend for employers. Even more eye opening, specialty medications account for more than 50% of total drug costs while serving less than 2 percent of members.¹ That imbalance alone should tell us something important. A very small number of claims can completely reshape a health plan’s financial performance.
And yet, many employers still treat pharmacy like a background function. Something that runs quietly. Something their carrier or PBM is handling.
This is where brokers have an opportunity.
The brokers who stand out are not the ones who wait until renewal to react. They are the ones who understand the blind spots and help employers see what has been hiding in plain sight.
Here are the most common Rx spend blind spots employers still have and how you can reframe the conversation.
The most common rx spend blind spots
“We just need better discounts”
This is one of the most common assumptions employers make.
If costs are rising, the solution must be better discounts. Bigger rebates. A stronger guarantee. A sharper negotiation.
But higher rebates do not automatically mean lower costs.
Many employers do not realize the difference between gross cost and net cost. They see a large rebate number at the end of the year and assume the plan performed well. What they often do not see is the total amount paid upfront, how pricing is structured, or whether spread pricing is quietly inflating costs along the way.
In some rebate driven models, the incentive is tied to higher list prices. That means the bigger the drug price, the bigger the rebate. On paper, that looks impressive. In practice, it does not always translate into real savings for the employer or lower out of pocket costs for employees.
This is where brokers can elevate the conversation. Instead of focusing only on discounts, shift the discussion to total net cost, pricing transparency, and alignment of incentives.
Better discounts are not the strategy. Better structure is.
“Our fully insured carrier handles pharmacy so we’re fine”
When pharmacy is bundled inside a fully insured plan, it feels simple. One contract. One renewal. One conversation.
But bundled does not always mean optimized.
In many cases, employers have very limited visibility into how their pharmacy benefit is actually performing. They may not see detailed claims data. They may not understand formulary decisions. They may not know how specialty drugs are being managed or how rebates are flowing.
Without transparency, there is no control. And without control, there is no strategy.
This is an opportunity for brokers to reposition the conversation. Instead of asking whether pharmacy is included, ask how it is performing. Instead of assuming it is handled, explore whether it is structured in the employer’s best interest.
Handling something is not the same as managing it strategically.
“Specialty drugs are rare and they won’t impact us”
This belief used to be more understandable. It is no longer realistic.
Specialty medications now account for more than half of total drug spend nationally while serving a very small percentage of members. That means a single high cost claimant can dramatically affect the financial performance of a plan.
One therapy. One diagnosis. One year of treatment. That can shift stop loss exposure, renewal leverage, and long term cost projections.
When employers think specialty is rare, they often underestimate risk. They budget based on averages instead of exposure.
Brokers who understand specialty trends can bring a different level of foresight. The conversation shifts from reacting to high cost claims to preparing for them. From surprise to strategy.
“If employees aren’t complaining, the plan is working”
Silence does not equal satisfaction.
Many employees do not fully understand their pharmacy benefits. They may not know there are alternative sourcing options. They may not question copay differences. They may simply pay what is in front of them and move on.
Meanwhile, out of pocket costs can increase quietly. Adherence can drop. Members may abandon prescriptions at the counter. None of that always shows up as a complaint.
A plan can appear stable on the surface while inefficiencies build underneath.
Brokers can reframe this by looking beyond noise. Instead of asking whether employees are upset, ask whether the benefit is optimized. Ask whether members are supported. Ask whether the structure encourages adherence or creates friction.
A quiet plan is not automatically an efficient one.
“All PBMs are basically the same”
This is where commodity thinking takes over.
If every Pharmacy Benefits Manager looks similar, the decision often comes down to discounts and familiarity. But not all models are built the same way.
Traditional PBMs tend to focus heavily on claims processing, rebate aggregation, and network management. A Pharmacy Benefit Solutions approach looks deeper. It examines contract alignment, specialty strategy, transparency, member advocacy, and long term cost control.
The structure matters. Incentives matter. Visibility matters.
For brokers, this is a positioning moment. When you understand the differences in models, you move from comparing vendors to evaluating strategy. And that is where real differentiation begins.
“Higher utilization means the plan is failing”
At first glance, rising utilization can feel like bad news. More prescriptions filled must mean higher costs. And higher costs must mean something is wrong.
Not necessarily.
In many cases, increased utilization reflects better adherence. Members are taking medications as prescribed. Chronic conditions are being managed. Preventive therapies are being filled instead of ignored.
That can lead to higher short term pharmacy spend but lower long term medical costs. Fewer complications. Fewer hospital visits. Better overall outcomes.
The key is distinguishing between unmanaged cost growth and strategic utilization. Brokers who understand this difference can help employers focus on long term cost containment instead of reacting to short term optics.
“Switching PBMs is too disruptive”
Change creates hesitation. Employers worry about employee confusion. Network changes. Implementation timelines. Service interruptions.
So they stay where they are.
But disruption is often overestimated. A structured transition plan with clear communication and defined milestones can minimize friction significantly. The real risk is not change. The real risk is remaining in a structure that is quietly underperforming year after year.
This is where brokers can shift the tone. Instead of framing a change as a disruption, frame it as a strategic move supported by planning, data review, and clear implementation support.
Stability matters. But so does improvement.
“Rx is only a small piece of total spend”
Many employers still view pharmacy as a secondary category compared to medical costs. It feels smaller. More contained.
In reality, pharmacy trend often outpaces medical trend. And certain drug categories can shift total plan performance quickly.
Pharmacy decisions affect stop loss exposure. They influence employee satisfaction and retention. They shape overall risk profile. They can either create predictability or introduce volatility.
When employers treat pharmacy as minor, they miss one of the most controllable cost levers in the entire health plan.
Brokers who highlight that connection elevate the conversation from line item review to total healthcare strategy.
“We’ll revisit pharmacy strategy at renewal”
This might be the most expensive blind spot of all.
Waiting until renewal turns strategy into reaction. By the time renewal arrives, trends are already established. High cost claimants have already impacted projections. Contract structures are already locked in for another cycle.
The most effective brokers use this period to educate. To analyze claims performance. To assess specialty exposure. To review contract alignment. To prepare employers before renewal pressure begins.
Q2 conversations often shape Q4 outcomes. The groundwork laid now determines whether renewal discussions feel controlled or chaotic.
Pharmacy strategy is not a once a year discussion. It is an ongoing lever.
A closer look at what employers often miss and how to talk about it
Intercept Rx explains that most employers focus primarily on their pharmacy renewal numbers without examining the underlying claim drivers, utilization patterns, or contract structure. Yet those deeper layers are often where meaningful savings opportunities exist. Looking only at a renewal summary can hide trends that quietly shape long term cost performance.
According to Intercept Rx’s pharmacy benefit analysis, employers frequently overestimate the value of rebate guarantees while underestimating the impact of specialty management strategies and contract transparency. Strong pharmacy performance is rarely about one headline number. It is about how the entire structure works together.
Now here is the important part for brokers.
Just because the structure is complex does not mean the conversation needs to be.
Employers are already overwhelmed by rising healthcare costs. They are managing budgets, employee concerns, compliance issues, and leadership expectations. If the pharmacy discussion becomes overly technical or feels like criticism of past decisions, resistance builds quickly.
This is where positioning matters.
The most effective brokers do not overwhelm employers with contract language or rebate math. They simplify. They translate. They connect pharmacy structure to real business impact.
Instead of pointing out mistakes, they guide employers toward clarity. Instead of creating urgency through pressure, they create confidence through education.
When you position yourself as a strategic partner rather than a critic, pharmacy becomes less intimidating and more actionable.
And that is where real change begins.
Final thoughts: The brokers who lead this conversation win
Pharmacy spend is no longer a passive part of the health plan.
It is not a background function. It is not just a renewal line item. And it is not something that runs on autopilot without consequences.
A small number of claims can reshape total plan performance. Contract structure can quietly influence long term costs. Specialty strategy can determine whether renewal feels controlled or chaotic.
The brokers who understand these nuances separate themselves quickly.
Not because they talk more. Not because they overwhelm clients with data. But because they ask better questions. They look deeper than the summary report. They connect pharmacy decisions to business outcomes like budget stability, stop loss exposure, and employee satisfaction.
Strategic education now leads to stronger positioning later. The conversations you guide today shape the leverage you have tomorrow.
And when brokers bring clarity to pharmacy strategy, employers begin to see it differently. Not as a cost they react to, but as a lever they can manage.
That shift changes everything.
Key Takeaways
- Pharmacy spend is a major driver of total healthcare cost, not a secondary category.
- Specialty medications can significantly impact financial performance even when only a few members are using them.
- Rebates and discounts do not always equal true savings. Structure matters.
- Transparency and contract alignment often matter more than headline guarantees.
- Increased utilization does not automatically signal failure. It may reflect improved adherence and long term value.
- Waiting until renewal limits strategy. Proactive conversations create leverage.
- Brokers who simplify complexity build trust and differentiate themselves.
- A thoughtful pharmacy strategy strengthens overall health plan performance.
